Literature DB >> 22324207

A report of 2 cases of myopericarditis after Vaccinia virus (smallpox) immunization.

Umesh Sharma1, Tahir Tak.   

Abstract

BACKGROUND: To counter the possibility of smallpox being used as a biological weapon, in 2002 the US government restarted a smallpox vaccination campaign. Myopericarditis is a possible cardiac complication of smallpox vaccination. We report 2 cases of vaccine-associated myopericarditis in military recruits who were treated at our facility. Chest pain, shortness of breath, and electrocardiographic changes of pericarditis, with a recent history of smallpox vaccination, were useful in making the diagnosis of probable post-vaccinial myopericarditis. Nonsteroidal, anti-inflammatory drugs (NSAIDs) were used to manage myopericarditis. Both patients had complete resolution of symptoms and electrocardiographic changes and subsequently returned to active duty.
CONCLUSION: Myopericarditis should be suspected when patients with recent history of smallpox vaccination present with chest pain or shortness of breath. Nonsteroidal anti-inflammatory drugs are useful in the management of post-vaccinial myopericarditis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22324207

Source DB:  PubMed          Journal:  WMJ        ISSN: 1098-1861


  4 in total

1.  Myocarditis secondary to smallpox vaccination.

Authors:  Kyle Keinath; Tyler Church; Benjamin Kurth; Edward Hulten
Journal:  BMJ Case Rep       Date:  2018-03-22

Review 2.  Cardiac Adverse Events after Vaccination-A Systematic Review.

Authors:  Kanak Parmar; Sai Subramanyam; Gaspar Del Rio-Pertuz; Pooja Sethi; Erwin Argueta-Sosa
Journal:  Vaccines (Basel)       Date:  2022-04-29

3.  Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population.

Authors:  Eva-Maria Zitzmann-Roth; Frank von Sonnenburg; Stephan de la Motte; Nathaly Arndtz-Wiedemann; Alfred von Krempelhuber; Nadine Uebler; Jens Vollmar; Garth Virgin; Paul Chaplin
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

4.  Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

Authors:  Edgar Turner Overton; Steven J Lawrence; Eva Wagner; Katrin Nopora; Siegfried Rösch; Philip Young; Darja Schmidt; Christian Kreusel; Sonja De Carli; Thomas P Meyer; Heinz Weidenthaler; Nathaly Samy; Paul Chaplin
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.